Oral alendronate treatment for polyostotic fibrous dysplasia: A case report

Journal of Orthopaedic Science

Volumn 9, Issue 5, 2004, Pages 521-525

  Kitagawa, Yasuyuki ^a   Tamai, Kensuke ^a   Ito, Hiromoto ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Alendronate; Bisphosphonate; Bone turnover; Fibrous dysplasia

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID;

ADULT; ALBRIGHT SYNDROME; ARTICLE; BONE RADIOGRAPHY; BONE TURNOVER; CASE REPORT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; OSTEOLYSIS; SIDE EFFECT;

EID: 6944219739     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-004-0809-0     Document Type: Article

References (23)

1. Bell NH, Avery S, Johnston CC Jr. Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Metab 1970;31:283-90.
2. Chapurlat RD, Delmas PD, Liens D, et al. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997;12:1746-52.
3. Dahlin DC, Unni KK. Bone tumors: general aspects and data on 8,542 cases. 4th ed. Springfield: Charles C Thomas; 1986. p. 413-20.
4. Devogelaer JP. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000;12:331-5.
5. Isaia GC, Lala R, Defilippi C, et al. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002;71:121-8.
6. Khadilker VV, Khadilker AV, Maskati GB. Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr 2003;40:894-6.
7. Koizumi M, Kobayashi M, Furukawa M, et al. The bisphosphonate incadronate for bone metastases of breast cancer. Int J Clin Oncol 2000;5:241-6.
8. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 2003;10:21-7.
9. Lala R, Matarazzo P, Bertelloni S, et al. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000;89:183-93.
10. Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 2001;382:6-12.
11. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-4.
12. Long A, Loughlin T, Towers RP, et al. Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: aetiological and therapeutic implications. Ir J Med Sci 1988;157:229-34.
13. Matarazzo P, Lala R, Masi G, et al. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;15:929-37.
14. Parisi MS, Oliveri MB, Acotto CG, et al. Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 2001;4:167-72.
15. Shiraki M, Kushida K, Fukunaga M, et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J 1998;45:191-201.
16. Singer FR. Fibrous dysplasia of bone: the bone lesion unmasked. Am J Pathol 1997;151:1511-15.
17. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
18. Vinholes J, Guo CY, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997;15:131-8.
19. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
20. Weinstein RS. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 1997;12:1314-15.
21. Yamamoto T, Ozono K, Kasayama S, et al. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996;98:30-5.
22. Yamamoto T, Ozono K, Shima M, et al. Alendronate and pharmacological doses of 1α OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia. J Bone Miner Metab 2002;20:170-3.
23. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000;137:403-9.